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Fig. 1. Effect of intravenous silibinin administration on the course of hepatitis C viremia (upper panel) and aminotransferase (ALT) and bilirubin levels (lower
panel) after liver transplantation. HCV RNA levels were measured by real-time PCR assay (Cobas AmpliPrep Taqman, Roche Diagnostics, Germany); ALT and bilirubin
levels are depicted as relative values of the upper limit of normal (ULN).
Letters to the Editor
9Combination of acarbose and ezetimibe prevents non-alcoholic
fatty liver disease: A break of intestinal insulin resistance?To the Editor:
We readwith great interest the study by Nozaki and colleagues
[1] that evaluated the effect of combination therapy of ezetimibe,
an intestinal cholesterol adsorption inhibitor, and acarbose, an
alpha glucosidase inhibitor, on the prevention of the high-fat diet
induced, non-alcoholic fatty liver disease (NAFLD) inmice. In their
study, the authors concluded that the combination of both drugs
for 24 weeks signiﬁcantly reduced steatosis, inﬂammation, and
ﬁbrosis in the liver of animals, compared to long-term mono-
therapy with either drug. Insulin resistance and liver steatosis
are interlinked metabolic abnormalities, whose prevalence is rap-
idly increasing worldwide [2]. We absolutely agree that the effec-
tive pharmacological therapy for prevention or treatment of
NAFLD does not exist today, and we thus acknowledge that the
recent study by Nozaki and colleagues has paved the way towards
a new therapeutic approach for the prevention and treatment of
NAFLD. However, we have some concerns regarding this study
and its conclusions, which are outlined as follows:
The authors use the high-fat diet which contains more than
57% of calories from fat and only 22.8% of carbohydrates to
induce the NAFLD in animals. Despite the importance of impair-
ment in the lipid metabolism and quantity of the dietary fat
intake for the development of NAFLD [2], the high carbohydrate
intake is also involved in the pathogens of NAFLD: ﬁrst, the ‘‘soft
drinks” without fat content were associated with hepatic steato-52 Journal of Hepatology 2sis independent of insulin resistance in humans [3]; second, die-
tary habits with high glycemic index were associated with liver
steatosis [4]. Thus, the additional model using the high glycemic
load were of interest for such experimental design. Another point
is the action of the acarbose in the studied dietary conditions: the
strong reduction of carbohydrate intake led to the diminished
action of acarbose and promising effects for ezetimibe. Interest-
ingly and surprisingly, the reduction of fasting glycemia and insu-
linemia under ezetimibe treatment was as pronounced as the
effects of the antidiabetic drug acarbose. Based on the principal
postprandial actions of both drugs, the data from oral stimulation
tests, such as oral glucose loading or meal test, could be of great
interest regarding the mechanisms of NAFLD prevention.
The major and very intriguing observation is the effect of the
combination of acarbose and ezetimibe during the progression of
NAFLD in the high-fat diet. The authors concluded two hypotheses
in order to explain the observed effects: (i) the additive ormultipli-
cative effects of both drugs on cholesterol reduction accompanying
the inhibition of gut glucose absorption lead to the improvement of
systemic insulin sensitivity and/or (ii) the promotion of lipid dis-
charge from the liver and the b-oxidation of lipids in the liver.
Regarding the ﬁrst hypothesis, after a 12-week high-dose acar-
bose treatment (300 mg/d), our data in humans showed no effects
on whole body insulin sensitivity, measured in the euglycemic
clamp, and no changes in body weight [5]. Moreover, we observed010 vol. 52 j 951–954
a strong and signiﬁcant decrease in the postprandial glucose and
insulin concentration as an index for the improvement in the intes-
tinal and hepatic insulin sensitivity. In the sub-group analysis of
subjects with an elevated hepatic fat content, we observed 26%
of the decrement under acarbose treatment [Rudovich et al.,
unpublished data], (Fig. 1). However, no deﬁnitive conclusion can
be drawn from this ﬁrst human data due to small observation sizes.
No data exists on the effects of ezetimibe on insulin sensitivity
in humans. Thus, the reduction in the body weight is primarily
responsible for the observed improvement of insulin sensitivity
under combination therapy in the study from Nozaki et al. [1].
The strongest effect of the combination therapy on the mark-
ers of the lipid metabolism in the liver was the upregulation of
the SREBP-2 gene. The authors consider this effect as a secondary
and compensative reaction of diminished hepatic cholesterol
synthesis. The upregulation of SREBP-2 under ezetimibe applica-
tion is not only a hepatic effect and was observed on the different
types of enteroendocrine cells of the gut [7]. Moreover, the secre-
tion of some gastro-intestinal hormones such as cholecystokinine
and glucagons-like peptide-1 are modulated by SREBP-2 via reg-
ulation of the sweet taste receptor expression [7]. Thus, the
upregulation of SREBP-2 under combination therapy of ezetimibe
and acarbose can lead to remarkable changes in the acute post-
prandial and chronic secretion of different gastro-intestinal hor-
mones. Based on the new mechanisms for the regulation of the
rate of production of triglyceride-rich lipoproteins in the gut
and the strong involvement of the gastro-intestinal hormones
in this process [8], the intestinal effects on the drug combination
studied are decisive for the observed prevention of NAFLD. More-
over, the modulation of gastro-intestinal hormone responses may
explain a dramatic weight reduction observed under combination
of acarbose and ezetimibe in this study.
In conclusion, the combination of ezetimibe and acarbose is a
very promising pharmacological strategy to prevent, and possibly
to treat, theNAFLD. The dysregulation of intestinal lipid and carbo-
hydrate metabolism, i.e. ‘‘intestinal insulin resistance” [8], seems
to be an important mechanism in the pathogenesis of NAFLD.
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Fig. 1. Effect of 12 weeks double-blind parallel group acarbose (n = 12) and
placebo treatment (n = 12) on hepatic fat content measured by magnetic
resonance spectroscopy. Data are presented as the means ± SEM. p in the two-
side paired T-test (baseline vs. end of the treatment (12 weeks)). Single voxel MRS
was performed on a 1.5 T whole body imager (Magnetom Vision, Siemens
Healthcare, Erlangen, Germany) in the morning after overnight fasting twice
during the study. All subjects have an elevated hepatic fat content (deﬁned as
hepatic fat content P6% [6]). Acarbose 50 mg was taken orally two times daily
(100 mg/d) in the ﬁrst titration week, 50 mg three times daily (150 mg/d) in the
second titration week and 100 mg three times daily (300 mg/d) with each meal in
the following treatment period (weeks 3–12).
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